• CPI-613 is a first-in-class agent with novel mechanism of action
  • It is a multi-targeted cancer metabolism product- targets altered energy metabolism in cancer cells (AEMD) and acts upon multiple molecules (PDH and KGDH)
  • It is highly selective to cancer cells
  • There are 14 ongoing or completed clinical trials on CPI-613 in multiple hematological malignancies and solid tumors:
    • Phase I trials in Acute Myeloid Leukemia, Colorectal Cancer, Hematologic Malignancies, Hodgkin's Lymphoma / Non-Hodgkin Lymphoma - B and T-cell Subtype and Pancreatic Cancer
    • PhaseI/II trials in Advanced Cancer / Lymphomas / Solid Tumors and Pancreatic Cancer
    • Phase II trials in Acute Myeloid Leukemia / Myelodysplastic Syndrome and Solid Tumors
  • It is granted ‘Orphan Drug’ status by US FDA for Acute Myeloid Leukemia, Myelodysplastic Syndrome and Pancreatic Cancer